Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.

  title={Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.},
  author={M. Uro{\vs}evi{\'c} and R. Dummer and C. Conrad and M. Beyeler and E. Laine and G. Burg and M. Gilliet},
  journal={Journal of the National Cancer Institute},
  volume={97 15},
  • M. Urošević, R. Dummer, +4 authors M. Gilliet
  • Published 2005
  • Medicine
  • Journal of the National Cancer Institute
  • BACKGROUND Imiquimod, an immune response modifier that is used topically to treat different types of skin cancer, induces the production of proinflammatory cytokines that stimulate an antitumor immune response. We assessed characteristics of the imiquimod-induced immune activation in epithelial and lymphoproliferative neoplasias of human skin. We focused on plasmacytoid predendritic cells (PDCs), the primary producer of interferon alpha (IFN-alpha) after imiquimod activation in vitro. METHODS… CONTINUE READING
    173 Citations
    Immunomodulation by imiquimod in patients with high-risk primary melanoma
    • 44
    Nature of Inflammatory Infiltrate in Superficial Cutaneous Malignancies During Topical Imiquimod Treatment
    • 59
    Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells
    • 318
    • PDF
    Plasmacytoid dendritic cell role in cutaneous malignancies.
    • 16
    Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin.
    • 74
    Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod
    • 20
    • PDF


    Imiquimod Treatment Induces Expression of Opioid Growth Factor Receptor
    • 33
    • PDF
    A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod.
    • 258
    • PDF
    Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%.
    • 76
    • PDF
    Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential
    • M. Stanley
    • Medicine
    • Clinical and experimental dermatology
    • 2002
    • 343